Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics is expected to experience increased operating expenses and cash burn as it prepares for the commercial launch of its primary product candidate OLC, which has a PDUFA date of June 29, 2026. Despite trimming projected sales for OLC and increasing OpEx assumptions, maintaining a Buy rating for UNCY is recommended due to the company's strong potential in addressing unmet medical needs in the kidney disease market and its plan to raise additional equity later in the year.

Bears say

Unicycive Therapeutics is facing multiple risks, including potential delays and challenges in bringing its products to market, obtaining reimbursement for its products, and successfully executing its commercial operations. Despite having a strong cash balance and commitments for additional capital, the company's current shareholders may face significant dilution due to the conversion of warrants. In addition, Unicycive is not expected to be profitable until 2027 and may need to raise additional capital, which could further dilute current investors. These risks, along with a lower DCF-derived price target of $40, contribute to our negative outlook on the stock.

Unicycive Therapeutics (UNCY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.